Almirall poaches Bayer exec to be chief scientific officer
Spanish skincare specialist Almirall (ALM: MC) has appointed Dr Karl Ziegelbauer as chief scientific officer of the company, effective July 7.
Dr Ziegelbauer joins Almirall from Germany’s Bayer (BAYN: DE), where he most recently served as senior vice president and head of open innovation and digital technologies. Almirall’s new CSO is a recognized industry leader and he brings with him three decades of leadership experience in drug discovery in international markets such as Germany, Japan, and the USA.
He has developed most of his career at Bayer Pharmaceuticals and he has been assuming positions of increasing responsibility, holding senior vice president roles in various medical research fields. His experience encompasses different specialties such as oncology, cardiovascular diseases, anti-infectives, and immunology/inflammation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze